TL;DR — Melatonin is the pineal indoleamine that sets circadian timing and doubles as a broad-spectrum, mitochondria-concentrated antioxidant. Its secretion falls sharply with age. The sleep-latency evidence is genuinely strong (multiple meta-analyses), so for sleep this is Tier A; the geroprotection story — better mitochondrial respiration, lower inflammatory markers, longer lifespan — is mostly preclinical or emerging human data, so as a longevity compound it earns Tier B honestly. Typical dose 0.5–5 mg, 30–60 min before bed; reassess sleep at 2–4 weeks.
What melatonin does (and why it matters)
Melatonin (N-acetyl-5-methoxytryptamine) is produced by the pineal gland at night and suppressed by light. Its first job is timekeeping: it is the body's chemical signal for "biological darkness," entraining the sleep–wake cycle, core body temperature, and downstream hormonal rhythms. Its second, less-appreciated job is redox defense — melatonin is a direct free-radical scavenger that concentrates in mitochondria, where most reactive oxygen species originate.
Both roles decay with age. Pineal melatonin secretion declines progressively across the lifespan, and by very old age nocturnal levels can fall to a small fraction of young-adult values (PMID 22724080, Aging Dis 2012). That decline is one of the more measurable examples of an age-related loss of intercellular signaling — which is exactly why melatonin shows up on longevity radar.
Primary hallmarks targeted: Mitochondrial dysfunction · Chronic inflammation · Altered intercellular communication
For sleep onset, the human evidence is real and repeated. Ferracioli-Oda et al. 2013 (PMID 23691095, PLoS One): a meta-analysis of 19 RCTs (n=1683) found melatonin significantly reduced sleep latency (WMD −7.06 min, 95% CI −4.37 to −9.75, p<0.001) and increased total sleep time. Buscemi et al. 2005 (PMID 16423108, J Gen Intern Med) found a smaller pooled latency reduction (−11.7 min overall) that was large for delayed sleep phase syndrome (−38.8 min) but modest for insomnia. A 2024 dose-response meta-analysis of 26 RCTs (PMID 38888087, J Pineal Res) found the latency benefit peaked around 4 mg/day — more is not better.
Mechanism — a hormone that is also an antioxidant
Melatonin is unusual: it acts both through membrane receptors (MT1/MT2) that drive circadian signaling and as a receptor-independent chemical antioxidant. The indole ring donates electrons to neutralize hydroxyl radical, peroxynitrite, and other reactive species, and several of its metabolites are themselves scavengers — a cascade in which one molecule can quench multiple radicals (PMID 11899100, Curr Top Med Chem 2002). Because it is amphiphilic and accumulates in mitochondria, that scavenging happens where oxidative damage is generated.
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| MT1/MT2 receptor signaling | Entrains circadian clock, promotes sleep onset | Altered intercellular communication |
| Direct ROS/RNS scavenging | Radical-quenching cascade in mitochondria | Mitochondrial dysfunction |
| Electron-transport support | Reported improvement in mitochondrial respiration/ATP | Mitochondrial dysfunction |
| NF-κB / cytokine modulation | Lower CRP and IL-6 in metabolic-syndrome trials | Chronic inflammation |
Where the evidence is strong vs. speculative
The circadian/sleep mechanism is well-established and backed by human RCTs — that part is not in doubt. The mitochondrial-respiration and anti-aging claims lean heavily on animal and cell work: the seminal review (PMID 11976199, Ann N Y Acad Sci 2002) reports melatonin stimulating electron transport and ATP synthesis while explicitly cautioning there is "no definitive proof" it slows aging in humans. Read the geroprotection framing as a plausible mechanism, not a demonstrated outcome.
Evidence summary — strong for sleep, thinner for longevity
| Study | Design | N | Key outcome | Tier |
|---|---|---|---|---|
| Ferracioli-Oda 2013 (PMID 23691095) | Meta-analysis, 19 RCTs | 1683 | ↓Sleep latency −7.06 min; ↑total sleep time | A |
| Buscemi 2005 (PMID 16423108) | Meta-analysis, primary sleep disorders | — | ↓Latency (large in DSPS, modest in insomnia) | A |
| Dose-response MA 2024 (PMID 38888087) | Meta-analysis, 26 RCTs | 1689 obs | Latency benefit peaks ~4 mg/day | A |
| Akbari 2018 (PMID 29907916) | Meta-analysis, 6 RCTs | 317 | ↓CRP and ↓IL-6; no TNF-α effect | B |
| Lauritzen 2021 (PMID 34370338) | Meta-analysis | — | Slight ↓fasting insulin; no fasting-glucose change | B |
| Reiter 2002 (PMID 11976199) | Mechanistic review | — | ↑Mitochondrial respiration; aging effect unproven | C |
← Swipe for more columns →
Consensus: Tier A for reducing sleep latency and supporting circadian timing. Tier B for anti-inflammatory and insulin-related metabolic signals — real but small, dose- and population-dependent. Tier C for direct geroprotection/lifespan, which remains preclinical. There is no human trial showing melatonin extends healthspanThe portion of life spent in good health, free from chronic disease or disability — distinct from lifespan (total years alive). Full glossary →; the longevity case rests on mechanism plus the age-related decline in endogenous levels.
Where melatonin disappoints
- The sleep effect is real but small. Meta-analyses put the latency reduction at roughly 7 minutes — helpful for phase-shifting (jet lag, delayed sleep phase), underwhelming for entrenched insomnia. - The anti-aging case is preclinical. Better mitochondrial respiration and lower inflammation come mostly from animal/cell work; no human trial shows it extends healthspan. - The bottle may not contain what it says. OTC melatonin is notoriously variable — measured content often deviates far from the label — so "it stopped working" can be a product problem, and more-is-better is false (benefit plateaus near 4 mg, grogginess rises past it).
Should you take melatonin?
Is your primary goal falling asleep faster or resetting a shifted sleep phase (jet lag, shift work, delayed sleep phase)?
Reasonable, well-evidenced use — start low (0.5–1 mg) 30–60 min before target bedtime and titrate only if needed
node | Are you adding it mainly as an antioxidant / anti-aging agent?
Be honest that this is Tier B/C — the mechanism is sound but no human healthspan outcome exists; treat it as a secondary rationale, not a headline benefit
A low PM dose is low-risk to trial, but don't expect effects beyond sleep quality
Pregnant, nursing, on anticoagulants/immunosuppressants/antiseizure or antihypertensive meds, or giving it to a child → physician clearance first
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Dose | 0.5–5 mg | Latency benefit plateaus near 4 mg (PMID 38888087); higher doses add side effects, not efficacy |
| Timing | 30–60 min before bed | For phase-shifting (jet lag/DSPS), earlier evening dosing can be more effective than at-bedtime |
| Form | Standard-release for latency | Prolonged-release is used for sleep-maintenance and in older adults |
| BioavailabilityHow much of a compound actually reaches your bloodstream and tissues after you take it. Full glossary → | Low and variable (~15%) | Extensive hepatic first-pass metabolism; blood levels vary widely between people |
| Duration before reassessing | 2–4 weeks | Sleep is a fast readout — if latency hasn't improved, more won't help |
Week-one compliance checklist
- [ ] Start at the lowest dose (0.5–1 mg) — melatonin is one of the few supplements where less is often as good as more
- [ ] Take it at a consistent time each night and dim lights afterward (bright light blunts its effect)
- [ ] Log sleep-onset time and morning grogginess; excess grogginess usually means the dose is too high or too late
Add melatonin to your stack
Melatonin sits in the PM/mitochondrial slot — Stack Architect updates its synergyWhen two compounds together produce greater effect than either alone. Full glossary → score when paired with mitochondrial-support and anti-inflammatory partners like CoQ10 and omega-3.
Open Stack ArchitectMonitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| Sleep-onset latency (self-tracked) | Faster / subjectively easier | Baseline, 2–4 wk | No change → lower or stop; melatonin isn't your lever |
| Morning alertness | No residual grogginess | Daily log | Grogginess → reduce dose or move earlier |
| hs-CRP | <1.0 mg/L | Baseline, 12 wk | Use only as a soft secondary signal — inflammation effect is modest |
| Fasting glucose / insulin | Stable | Baseline, 12 wk | Metabolic effect is small; don't rely on melatonin here |
← Swipe for more columns →
Safety, red flags, and contraindications
- Generally well tolerated short-term — most common effects are next-day grogginess, headache, dizziness, and vivid dreams, usually dose-related.
- Not physically addictive — no recognized withdrawal syndrome, unlike sedative-hypnotics; the main risk is psychological reliance.
- Supplement-grade variability — over-the-counter products are unregulated and actual content has been shown to deviate substantially from label; source matters.
Clear it with a physician before starting if any apply
- Pregnancy or nursing — insufficient safety data; avoid unless a clinician directs otherwise.
- Children/adolescents — use only under pediatric supervision; effects on the developing hypothalamic-pituitary axis are not fully characterized.
- Anticoagulants, immunosuppressants, antihypertensives, antidiabetic or antiseizure medication — melatonin can interact; some drugs (e.g. fluvoxamine) sharply raise melatonin levels.
- Daytime drowsiness / driving — do not dose before activities needing alertness; residual sedation is real.
- Autoimmune conditions — melatonin is immunomodulatory; discuss before regular use.
What would change this grade. Melatonin is already A for sleep latency — settled. The geroprotection grade is C and would rise only with human healthspan trials tying its mitochondrial/anti-inflammatory mechanism to real outcomes; until then, treat "anti-aging melatonin" as a hypothesis.
Who should skip melatonin
- Anyone taking it mainly as an anti-aging antioxidant — that rationale is preclinical; use it for sleep, not lifespan. - Pregnancy/nursing, children/adolescents, or autoimmune conditions — insufficient or complicating safety data; clinician-directed only. - People needing sleep maintenance (staying asleep) — melatonin mainly shortens onset; it's not a hypnotic.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| Magnesium | Complementary sleep-support mechanism; commonly co-dosed in the PM | Magnesium module |
| Glycine | Independent evening sleep-quality mechanism (thermoregulation) — additive, not redundant | Glycine module |
| CoQ10 | Overlapping mitochondrial-antioxidant rationale — evaluate as shared, not stacked, coverage | CoQ10 module |
| Omega-3 | Anti-inflammatory effect complements melatonin's modest CRP/IL-6 signal | Omega-3 module |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Fluvoxamine (and some other CYP1A2 inhibitors) | Sharply raise melatonin blood levels, amplifying sedation | Physician review; expect a much lower effective dose |
| Evening bright light / screens | Light suppresses melatonin signaling and blunts the dose | Dim lights after dosing or the effect is wasted |
| Sedatives / alcohol | Additive next-day grogginess and impairment | Don't combine before anything needing alertness |
Personal results template
My Melatonin results log
| Date | Week | Dose | Sleep latency | Morning alertness (1–10) | hs-CRP | Notes |
|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | Baseline |
| YYYY-MM-DD | 2–4 | 0.5–5 mg PM | — | — | — | Primary sleep endpoint |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: Falling asleep noticeably faster with no next-day grogginess. - No effect: No latency change after 2–4 weeks at a sensible dose — melatonin isn't your bottleneck; stop rather than escalate. - Stop and reassess: Persistent morning grogginess, vivid/disturbing dreams, or mood changes.
Log your experiment
Melatonin is one of the fastest compounds to evaluate — a 2–4 week sleep log tells you almost everything. Track it and move on.
Personal journeyReferences
- PMID 22724080
- PMID 23691095
- PMID 16423108
- PMID 38888087
- PMID 11899100
- PMID 11976199
- PMID 29907916
- PMID 34370338
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.